Talimogene Laherparepvec

BreastfeedingPediatric
  • TRADE NAME: Imlygic (Amgen)
  • INDICATIONS: Unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
  • SYNONYM: T-VEC
  • CLASS: Oncolytic virus immunotherapy
  • HALF-LIFE: N/A

FDA APPROVAL DATE: 10/27/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
Contraception advised to prevent pregnancy during treatment

Our database has 24 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
RENAL
LOCAL


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of talimogene laherparepvec in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric